Developing drugs that target the Wnt pathway: recent approaches in cancer and neurodegenerative diseases

Expert Opinion on Drug Discovery

Volumn 12, Issue 2, 2017, Pages 169-186

  Serafino, Annalucia ^a   Sferrazza, Gianluca ^a   Colini Baldeschi, Arianna ^a   Nicotera, Giuseppe ^a   Andreola, Federica ^a   Pittaluga, Eugenia ^a   Pierimarchi, Pasquale ^a  

^a INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

Author keywords

agents targeting Wnt signaling; cancer therapy; clinical trials; Parkinson s disease; preclinical studies; Wnt catenin pathway

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CWP 232291; IPAFRICEPT; LY 2090314; NOOTROPIC AGENT; PRI 724; UNCLASSIFIED DRUG; VANTICTUMAB; WNT PROTEIN; ANTIPARKINSON AGENT;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CARCINOGENESIS; DISEASE ASSOCIATION; DRUG TARGETING; HUMAN; NEOPLASM; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRECLINICAL STUDY; PRIORITY JOURNAL; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; WNT SIGNALING PATHWAY; ADULT; ANIMAL; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG EFFECTS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; WNT SIGNALING;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIPARKINSON AGENTS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PROGNOSIS; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

EID: 85008512072     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1080/17460441.2017.1271321     Document Type: Review

References (133)

1. Croce JC, McClay DR., Evolution of the Wnt pathways. Methods Mol Biol. 2008;469:3–18. DOI:10.1007/978-1-60327-469-2_1
2. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781–810. DOI:10.1146/annurev.cellbio.20.010403.113126• This article is one of the first review that highlighted the importance of Wnt signaling in development of diseases.
3. Van Amerongen R, Nusse R. Towards an integrated view of Wnt signaling in development. Development. 2009;136:3205–3214. DOI:10.1242/dev.033910
4. Pinto D, Clevers H. Wnt control of stem cells and differentiation in the intestinal epithelium. Exp Cell Res. 2005;306:357–363. DOI:10.1016/j.yexcr.2005.02.022
5. Nemeth MJ, Mak KK, Yang Y, et al. Beta-catenin expression in the bone marrow microenvironment is required for long-term maintenance of primitive hematopoietic cells. Stem Cells. 2009;27:1109–1119. DOI:10.1002/stem.32
6. Malhotra S, Kincade PW. Wnt-related molecules and signaling pathway equilibrium in hematopoiesis. Cell Stem Cell. 2009;4:27–36. DOI:10.1016/j.stem.2008.12.004
7. Inestrosa NC, Arenas E. Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci. 2010;11:77–86. DOI:10.1038/nrn2755
8. Monga SP. Role of Wnt/beta-catenin signaling in liver metabolism and cancer. Int J Biochem Cell Biol. 2011;43:1021–1029. DOI:10.1016/j.biocel.2009.09.001
9. Whyte JL, Smith AA, Helms JA. Wnt signaling and injury repair. Cold Spring Harb Perspect Biol. 2012;4:a008078. DOI:10.1101/cshperspect.a008078
10. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 2004;303:1483–1487. DOI:10.1126/science.1094291• This article is one of the first review that assembled evidence of possible interrelations between Wnt,β-catenin functions, and cadherin-mediated adhesion.
11. Moon RT, Kohn AD, De Ferrari GV, et al. WNT and beta-catenin signalling:diseases and therapies. Nat Rev Genet. 2004;5:691–701. DOI:10.1038/nrg1427•• This is one of the most important review that emphasized the role of dysregulation of Wnt/β-catenin signaling in disease insurgence, most notably cancer.
12. Berwick DC, Harvey K. The importance of Wnt signalling for neurodegeneration in Parkinson’s disease. Biochem Soc Trans. 2012;40:1123–1128. DOI:10.1042/BST20120122• This article is one of the first review that highlighted the importance of dysregulation of Wnt signaling in development of Parkinson’s disease
13. Inestrosa NC, Montecinos-Oliva C, Fuenzalida M. Wnt signaling:role in Alzheimer disease and schizophrenia. J Neuroimmune Pharmacol. 2012;7:788–807. DOI:10.1007/s11481-012-9417-5
14. Okerlund ND, Cheyette BN. Synaptic Wnt signaling-a contributor to major psychiatric disorders?. J Neurodev Disord. 2011;3:162–174. DOI:10.1007/s11689-011-9083-6
15. Libro R, Bramanti P, Mazzon E. The role of the Wnt canonical signaling in neurodegenerative diseases. Life Sci. 2016;158:78–88. DOI:10.1016/j.lfs.2016.06.024
16. Schinner S. Wnt-signalling and the metabolic syndrome. Horm Metab Res. 2009;41:159–163. DOI:10.1055/s-0028-1119408
17. Schinner S, Willenberg HS, Schott M, et al. Pathophysiological aspects of Wnt-signaling in endocrine disease. Eur J Endocrinol. 2009;160:731–737. DOI:10.1530/EJE-08-0831
18. Chilosi M, Poletti V, Zamo A, et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol. 2003;162:1495–1502.
19. Tao H, Yang JJ, Shi KH, et al. Wnt signaling pathway in cardiac fibrosis:new insights and directions. Metabolism. 2016;65:30–40. DOI:10.1016/j.metabol.2015.10.013
20. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11–26. DOI:10.1038/nrc3419•• This is a very interesting article published in 2013 that reviewed the complex roles for WNT signaling in cancer initiation and progression and highlighted how the discovery of agents modulating these pathways might improve cancer therapy.
21. Luu HH, Zhang R, Haydon RC, et al. Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets. 2004;4:653–671.•• This article is one of the first review that discussed some of the strategies explored for targeting key components of the Wnt/beta-catenin signaling pathway in anticancer drug discovery.
22. L’Episcopo F, Tirolo C, Caniglia S, et al. Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson’s disease. J Mol Cell Biol. 2014;6:13–26. DOI:10.1093/jmcb/mjt053•• This is an interesting review that highlights the emerging link between Wnt/β-catenin signaling and key inflammatory pathways during mDA neuron damage/repair in Parkinson’s disease progression.
23. Wan W, Xia S, Kalionis B, et al. The role of Wnt signaling in the development of Alzheimer’s disease:a potential therapeutic target?. Biomed Res Int. 2014;2014:301575. DOI:10.1155/2014/301575
24. Kahn M. Can we safely target the WNT pathway?. Nat Rev Drug Discov. 2014;13:513–532. DOI:10.1038/nrd4233•• This is an exhaustive article where most of the recent efforts of modulating Wnt signaling cascade for treatment of cancer, neurological diseases, osteoporosis, fibrosis, regenerative medicine and endocrine dysfunctions are reviewed and critically analyzed, reporting the main therapeutic approaches and drugs that have been explored in preclinical and clinical studies until the 2014.
25. Niehrs C. The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol. 2012;13:767–779. DOI:10.1038/nrm3470
26. Angers S, Moon RT. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol. 2009;10:468–477. DOI:10.1038/nrm2717
27. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling:components, mechanisms, and diseases. Dev Cell. 2009;17:9–26. DOI:10.1016/j.devcel.2009.06.016
28. Willert K, Nusse R. Wnt proteins. Cold Spring Harb Perspect Biol. 2012;4:a007864. DOI:10.1101/cshperspect.a007864
29. Gomez-Orte E, Saenz-Narciso B, Moreno S, et al. Multiple functions of the noncanonical Wnt pathway. Trends Genet. 2013;29:545–553. DOI:10.1016/j.tig.2013.06.003
30. He X, Semenov M, Tamai K, et al. LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling:arrows point the way. Development. 2004;131:1663–1677. DOI:10.1242/dev.01117
31. Ozawa M, Baribault H, Kemler R. The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. Embo J. 1989;8:1711–1717.• This is one of the first article that identified β-catenin (named at that time uvomorulin) as a protein interacting with the cell adhesion molecule E-cadherin at the cell-cell junction.
32. Vestweber D, Kemler R. Some structural and functional aspects of the cell adhesion molecule uvomorulin. Cell Differ. 1984;15:269–273.• This is one of the first article that reported the structural characterization of β-catenin (named at that time uvomorulin) and suggested its role as cell adhesion molecule regulating epithelial cell adhesion mechanisms.
33. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012;149:1192–1205. DOI:10.1016/j.cell.2012.05.012•• This is a quite recent review that provides an update of the Wnt/β-catenin signaling pathway, discuss how its various components contribute to diseases, and highlights some questions in the Wnt field that has not yet been addressed.
34. Fukumoto S, Hsieh CM, Maemura K, et al. Akt participation in the Wnt signaling pathway through Dishevelled. J Biol Chem. 2001;276:17479–17483. DOI:10.1074/jbc.C000880200
35. Serafino A, Moroni N, Psaila R, et al. Anti-proliferative effect of atrial natriuretic peptide on colorectal cancer cells:evidence for an Akt-mediated cross-talk between NHE-1 activity and Wnt/beta-catenin signaling. Biochim Biophys Acta. 2012;1822:1004–1018. DOI:10.1016/j.bbadis.2012.02.016
36. Tamai K, Zeng X, Liu C, et al. A mechanism for Wnt coreceptor activation. Mol Cell. 2004;13:149–156.
37. Li VS, Ng SS, Boersema PJ, et al. Wnt signaling through inhibition of beta-catenin degradation in an intact Axin1 complex. Cell. 2012;149:1245–1256. DOI:10.1016/j.cell.2012.05.002• This article that provided evidence for a novel regulatory model of Wnt/β-catenin signaling, according to which inhibition of β-catenin degradation occurs in an intact Axin1 complex.
38. Najdi R, Holcombe RF, Waterman ML. Wnt signaling and colon carcinogenesis:beyond APC. J Carcinog. 2011;10:5. DOI:10.4103/1477-3163.78111
39. He B, Reguart N, You L, et al. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene. 2005;24:3054–3058. DOI:10.1038/sj.onc.1208511
40. DeAlmeida VI, Miao L, Ernst JA, et al. The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res. 2007;67:5371–5379. DOI:10.1158/0008-5472.CAN-07-0266
41. Gong Y, Bourhis E, Chiu C, et al. Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies. Plos One. 2010;5:e12682. DOI:10.1371/journal.pone.0012682
42. Ettenberg SA, Charlat O, Daley MP, et al. Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proc Natl Acad Sci U S A. 2010;107:15473–15478. DOI:10.1073/pnas.1007428107
43. Grandy D, Shan J, Zhang X, et al. Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J Biol Chem. 2009;284:16256–16263. DOI:10.1074/jbc.M109.009647
44. Curtin JC. Novel drug discovery opportunities for colorectal cancer. Expert Opin Drug Discov. 2013;8:1153–1164. DOI:10.1517/17460441.2013.807249
45. Lepourcelet M, Chen YN, France DS, et al. Small-molecule antagonists of the oncogenic tcf/beta-catenin protein complex. Cancer Cell. 2004;5:91–102.
46. Eguchi M, Nguyen C, Lee SC, et al. ICG-001, a novel small molecule regulator of TCF/beta-catenin transcription. Med Chem. 2005;1:467–472.
47. Lenz HJ, Kahn M. Safely targeting cancer stem cells via selective catenin coactivator antagonism. Cancer Sci. 2014;105:1087–1092. DOI:10.1111/cas.12471
48. El-Khoueiry AB, Ning Y, Yang DY, et al. A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 2013;31. DOI:10.1200/JCO.2013.49.0219
49. Gray JE, Infante JR, Brail LH, et al. A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin. Invest New Drugs. 2015;33:1187–1196. DOI:10.1007/s10637-015-0278-7
50. Rizzieri DA, Cooley S, Odenike O, et al. An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia. Leuk Lymphoma. 2016;57:1800–1806. DOI:10.3109/10428194.2015.1122781
51. Cortes JE, Faderl S, Pagel J, et al. Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Journal of Clinical Oncology. 2015;33.(suppl; abstr 7044).
52. Park JW, Park JM, Green JE, et al. Long-term effect of Wnt/beta-catenin small molecule inhibitor CWP232291 on intestinal carcinogenesis in novel GEM model deficient in Smad4 and p53. Journal of Clinical Oncology. 2016;34.(suppl 4S; abstr 594).
53. Jimeno A, Gordon MS, Chugh R, et al. A first-in-human phase 1 study of anticancer stem cell agent OMP-54F28 (FZDS-Fe), decoy receptor for WNT ligands, in patients with advanced solid tumors. Journal of Clinical Oncology. 2014;32. DOI:10.1200/JCO.2013.54.6911
54. Smith DC, Rosen LS, Chugh R, et al. First-in-human evaluation of the human monoclonal antibody vantictumab (OMP-18R5; anti-frizzled) targeting the WNT pathway in a phase I study for patients with advanced solid tumors. Journal of Clinical Oncology. 2013;31. DOI:10.1200/JCO.2013.49.0219
55. ClinicalTrials.Gov. https://clinicaltrials.gov [cited 30Sep 2016]
56. Lee HJ, Wang NX, Shi DL, et al. Sulindac inhibits canonical Wnt signaling by blocking the PDZ domain of the protein dishevelled. Angew Chem Int Ed Engl. 2009;48:6448–6452. DOI:10.1002/anie.200902981
57. Bos CL, Diks SH, Hardwick JC, et al. Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis. 2006;27:2371–2382. DOI:10.1093/carcin/bgl071
58. Gurpinar E, Grizzle WE, Piazza GA. NSAIDs inhibit tumorigenesis, but how?. Clin Cancer Res. 2014;20:1104–1113. DOI:10.1158/1078-0432.CCR-13-1573
59. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov. 2006;5:997–1014. DOI:10.1038/nrd2154• This review provides an overview, until 2006, of the promise and pitfalls of drug development strategies attempting to inhibit the Wnt pathway for therapeutic intervention mainly in colon cancer, also analyzing existing drugs approved for other therapeutic indications, such as NSAIDs and vitamin derivatives.
60. Munding J, Ziebarth W, Pox CP, et al. The influence of 5-aminosalicylic acid on the progression of colorectal adenomas via the beta-catenin signaling pathway. Carcinogenesis. 2012;33:637–643. DOI:10.1093/carcin/bgr306
61. Gala MK, Chan AT. Molecular pathways:aspirin and Wnt signaling-a molecularly targeted approach to cancer prevention and treatment. Clin Cancer Res. 2015;21:1543–1548. DOI:10.1158/1078-0432.CCR-14-0877
62. Grosch S, Tegeder I, Niederberger E, et al. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. Faseb J. 2001;15:2742–2744. DOI:10.1096/fj.01-0299fje
63. Maier TJ, Janssen A, Schmidt R, et al. Targeting the beta-catenin/APC pathway:a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Faseb J. 2005;19:1353–1355. DOI:10.1096/fj.04-3274fje
64. Smith ML, Hawcroft G, Hull MA. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells:evidence of different mechanisms of action. Eur J Cancer. 2000;36:664–674.
65. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328:1313–1316. DOI:10.1056/NEJM199305063281805
66. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994;5:138–146.
67. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883–890. DOI:10.1056/NEJMoa021633
68. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891–899. DOI:10.1056/NEJMoa021735
69. Boon EM, Keller JJ, Wormhoudt TA, et al. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer. 2004;90:224–229. DOI:10.1038/sj.bjc.6601505
70. Ng K, Meyerhardt JA, Chan AT, et al. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst. 2015;107:345. DOI:10.1093/jnci/dju345
71. ASPirin Intervention for the REDuction of Colorectal Cancer Risk (ASPIRED). [cited; Available from:https://clinicaltrials.gov/ct2/show/NCT02394769
72. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A. 1996;93:8455–8459.
73. Pendas-Franco N, Aguilera O, Pereira F, et al. Vitamin D and Wnt/beta-catenin pathway in colon cancer:role and regulation of DICKKOPF genes. Anticancer Res. 2008;28:2613–2623.
74. Chen X, Duan N, Zhang C, et al. Survivin and Tumorigenesis:Molecular Mechanisms and Therapeutic Strategies. J Cancer. 2016;7:314–323. DOI:10.7150/jca.13332
75. Jaiswal AS, Marlow BP, Gupta N, et al. Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene. 2002;21:8414–8427. DOI:10.1038/sj.onc.1205947
76. Park CH, Chang JY, Hahm ER, et al. Quercetin, a potent inhibitor against beta-catenin/Tcf signaling in SW480 colon cancer cells. Biochem Biophys Res Commun. 2005;328:227–234. DOI:10.1016/j.bbrc.2004.12.151
77. Roccaro AM, Leleu X, Sacco A, et al. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenstrom’s macroglobulinemia. Clin Cancer Res. 2008;14:1849–1858. DOI:10.1158/1078-0432.CCR-07-1750
78. Huang SM, Mishina YM, Liu S, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009;461:614–620. DOI:10.1038/nature08356
79. Lehtio L, Chi NW, Krauss S. Tankyrases as drug targets. Febs J. 2013;280:3576–3593. DOI:10.1111/febs.12320
80. Lau T, Chan E, Callow M, et al. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res. 2013;73:3132–3144. DOI:10.1158/0008-5472.CAN-12-4562
81. Ma L, Wang X, Jia T, et al. Tankyrase inhibitors attenuate WNT/beta-catenin signaling and inhibit growth of hepatocellular carcinoma cells. Oncotarget. 2015;6:25390–25401. DOI:10.18632/oncotarget.4455
82. Ho SY, Keller TH. The use of porcupine inhibitors to target Wnt-driven cancers. Bioorg Med Chem Lett. 2015;25:5472–5476. DOI:10.1016/j.bmcl.2015.10.032
83. Gonsalves FC, Klein K, Carson BB, et al. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc Natl Acad Sci U S A. 2011;108:5954–5963. DOI:10.1073/pnas.1017496108
84. Catrow JL, Zhang Y, Zhang M, et al. Discovery of selective small-molecule inhibitors for the beta-catenin/t-cell factor protein-protein interaction through the optimization of the acyl hydrazone moiety. J Med Chem. 2015;58:4678–4692. DOI:10.1021/acs.jmedchem.5b00223
85. Chartier C, Raval J, Axelrod F, et al. Therapeutic targeting of tumor-derived r-spondin attenuates beta-catenin signaling and tumorigenesis in multiple cancer types. Cancer Res. 2016;76:713–723. DOI:10.1158/0008-5472.CAN-15-0561
86. De Lau W, Peng WC, Gros P, et al. The R-spondin/lgr5/rnf43 module:regulator of Wnt signal strength. Genes Dev. 2014;28:305–316. DOI:10.1101/gad.235473.113
87. Vesely DL. Cardiac and renal hormones:anticancer effects in vitro and in vivo. J Investig Med. 2009;57:22–28. DOI:10.2310/JIM.0b013e3181948b25
88. Skelton W, Skelton M, Vesely DL. Central role of beta-catenin in anticancer effects of cardiac hormones. Anticancer Res. 2013;33:2409–2414.
89. Skelton W, Skelton M, Vesely DL. Cardiac hormones are potent inhibitors of secreted frizzled-related protein-3 in human cancer cells. Exp Ther Med. 2013;5:475–478. DOI:10.3892/etm.2012.806
90. Serafino A, Moroni N, Zonfrillo M, et al. WNT-pathway components as predictive markers useful for diagnosis, prevention and therapy in inflammatory bowel disease and sporadic colorectal cancer. Oncotarget. 2014;5:978–992. DOI:10.18632/oncotarget.1571• This paper purchases evidence that crucial components of the Wnt/β-catenin pathway, when evaluated by a multiparametric approach, could be potent markers for diagnosis, prevention and therapy in IBD and sporadic colorectal cancer, also possessing a predictive value for responsiveness to Wnt-targeting therapies.
91. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer:the evolving field of molecular pathological epidemiology. J Natl Cancer Inst. 2010;102:365–367. DOI:10.1093/jnci/djq031
92. Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia:an emerging transdisciplinary and interdisciplinary field. Gut. 2011;60:397–411. DOI:10.1136/gut.2010.217182
93. Ogino S, Galon J, Fuchs CS, et al. Cancer immunology–analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol. 2011;8:711–719. DOI:10.1038/nrclinonc.2011.122
94. Nishi A, Milner DA, Jr., Giovannucci EL, et al. Integration of molecular pathology, epidemiology and social science for global precision medicine. Expert Rev Mol Diagn. 2016;16:11–23. DOI:10.1586/14737159.2016.1115346
95. Lochhead P, Chan AT, Giovannucci E, et al. Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. Am J Gastroenterol. 2014;109:1205–1214. DOI:10.1038/ajg.2014.153
96. Hamada T, Keum N, Nishihara R, et al. Molecular pathological epidemiology:new developing frontiers of big data science to study etiologies and pathogenesis. J Gastroenterol. 2016. DOI:10.1007/s00535-016-1272-3
97. Morikawa T, Kuchiba A, Yamauchi M, et al. Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. Jama. 2011;305:1685–1694. DOI:10.1001/jama.2011.513
98. Morikawa T, Kuchiba A, Lochhead P, et al. Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with beta-catenin (CTNNB1) status. Cancer Res. 2013;73:1600–1610. DOI:10.1158/0008-5472.CAN-12-2276
99. Nan H, Morikawa T, Suuriniemi M, et al. Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J Natl Cancer Inst. 2013;105:1852–1861. DOI:10.1093/jnci/djt331
100. Hornykiewicz O. Parkinson’s disease and its chemotherapy. Biochem Pharmacol. 1975;24:1061–1065.
101. Hirsch EC, Jenner P, Przedborski S. Pathogenesis of Parkinson’s disease. Mov Disord. 2013;28:24–30. DOI:10.1002/mds.25032
102. Olanow CW, Schapira AH. Therapeutic prospects for Parkinson disease. Ann Neurol. 2013;74:337–347. DOI:10.1002/ana.24011
103. Harrison-Uy SJ, Pleasure SJ. Wnt signaling and forebrain development. Cold Spring Harb Perspect Biol. 2012;4:a008094. DOI:10.1101/cshperspect.a008094
104. Salinas PC. Wnt signaling in the vertebrate central nervous system:from axon guidance to synaptic function. Cold Spring Harb Perspect Biol 2012;4. DOI:10.1101/cshperspect.a008003
105. Zhang L, Yang X, Yang S, et al. The Wnt /beta-catenin signaling pathway in the adult neurogenesis. Eur J Neurosci. 2011;33:1–8. DOI:10.1111/j.1460-9568.2010.7483.x
106. L’Episcopo F, Tirolo C, Testa N, et al. Plasticity of subventricular zone neuroprogenitors in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson’s disease involves cross talk between inflammatory and Wnt/beta-catenin signaling pathways:functional consequences for neuroprotection and repair. J Neurosci. 2012;32:2062–2085. DOI:10.1523/JNEUROSCI.5259-11.2012•• This is an interesting study in which the Authors, using in vivo, ex vivo, and in vitro experiments, provide evidence for an active role of astrocytes and microglia in the remodeling of the SVZ in a murine model of Parkinson’s disease, demonstrating that pharmacological modulation of inflammation prevented β-catenin downregulation and restored neurogenesis, with potential consequences for DAergic neuroprotection and self-repair.
107. L’Episcopo F, Tirolo C, Testa N, et al. Aging-induced Nrf2-ARE pathway disruption in the subventricular zone drives neurogenic impairment in parkinsonian mice via PI3K-Wnt/beta-catenin dysregulation. J Neurosci. 2013;33:1462–1485. DOI:10.1523/JNEUROSCI.3206-12.2013
108. L’Episcopo F, Serapide MF, Tirolo C, et al. A Wnt1 regulated frizzled-1/beta-catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk:therapeutical relevance for neuron survival and neuroprotection. Mol Neurodegener. 2011;6:49. DOI:10.1186/1750-1326-6-49
109. L’Episcopo F, Tirolo C, Testa N, et al. Reactive astrocytes and Wnt/beta-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. Neurobiol Dis. 2011;41:508–527. DOI:10.1016/j.nbd.2010.10.023
110. Berwick DC, Harvey K. The regulation and deregulation of Wnt signaling by PARK genes in health and disease. J Mol Cell Biol. 2014;6:3–12. DOI:10.1093/jmcb/mjt037
111. L’Episcopo F, Tirolo C, Testa N, et al. Wnt/beta-catenin signaling is required to rescue midbrain dopaminergic progenitors and promote neurorepair in ageing mouse model of Parkinson’s disease. Stem Cells. 2014;32:2147–2163. DOI:10.1002/stem.1708• This is an interesting study in which the Authors, using in vitro cell culture systems and in vivo models of PD, provide evidence suggesting the possibility for mDA neuron restoration by activating Wnt/β-catenin signaling in Wnt-responsive endogenous sources, with implications for regenerative medicine in PD.
112. L’Episcopo F, Tirolo C, Testa N, et al. Switching the microglial harmful phenotype promotes lifelong restoration of subtantia nigra dopaminergic neurons from inflammatory neurodegeneration in aged mice. Rejuvenation Res. 2011;14:411–424. DOI:10.1089/rej.2010.1134
113. Wei L, Sun C, Lei M, et al. Activation of Wnt/beta-catenin pathway by exogenous Wnt1 protects SH-SY5Y cells against 6-hydroxydopamine toxicity. J Mol Neurosci. 2013;49:105–115. DOI:10.1007/s12031-012-9900-8
114. Zhang L, Cen L, Qu S, et al. Enhancing beta-catenin activity via gsk3beta inhibition protects pc12 cells against rotenone toxicity through nurr1 induction. Plos One. 2016;11:e0152931. DOI:10.1371/journal.pone.0152931
115. Zhou T, Zu G, Zhang X, et al. Neuroprotective effects of ginsenoside Rg1 through the Wnt/beta-catenin signaling pathway in both in vivo and in vitro models of Parkinson’s disease. Neuropharmacology. 2016;101:480–489. DOI:10.1016/j.neuropharm.2015.10.024
116. Dong J, Li S, Mo JL, et al. Nurr1-Based Therapies for Parkinson’s Disease. CNS Neurosci Ther. 2016;22:351–359.
117. Silva-Alvarez C, Arrazola MS, Godoy JA, et al. Canonical Wnt signaling protects hippocampal neurons from abeta oligomers:role of non-canonical Wnt-5a/Ca(2+) in mitochondrial dynamics. Front Cell Neurosci. 2013;7:97. DOI:10.3389/fncel.2013.00097
118. Wolozin B, Wang SW, Li NC, et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease. BMC Med. 2007;5:20. DOI:10.1186/1741-7015-5-20
119. Zhang C, Wu JM, Liao M, et al. The rock/ggtase pathway are essential to the proliferation and differentiation of neural stem cells mediated by Simvastatin. J Mol Neurosci. 2016. DOI:10.1007/s12031-016-0811-y
120. Robin NC, Agoston Z, Biechele TL, et al. Simvastatin promotes adult hippocampal neurogenesis by enhancing Wnt/beta-catenin signaling. Stem Cell Reports. 2014;2:9–17. DOI:10.1016/j.stemcr.2013.11.002
121. Parish CL, Arenas E. Stem-cell-based strategies for the treatment of Parkinson’s disease. Neurodegener Dis. 2007;4:339–347. DOI:10.1159/000101892
122. Grealish S, Drouin-Ouellet J, Parmar M. Brain repair and reprogramming:the route to clinical translation. J Intern Med. 2016;280:265–275. DOI:10.1111/joim.12475
123. Parish CL, Castelo-Branco G, Rawal N, et al. Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J Clin Invest. 2008;118:149–160. DOI:10.1172/JCI32273
124. Hargus G, Cooper O, Deleidi M, et al. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci U S A. 2010;107:15921–15926. DOI:10.1073/pnas.1010209107
125. Kriks S, Shim JW, Piao J, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature. 2011;480:547–551. DOI:10.1038/nature10648
126. Arenas E. Wnt signaling in midbrain dopaminergic neuron development and regenerative medicine for Parkinson’s disease. J Mol Cell Biol. 2014;6:42–53. DOI:10.1093/jmcb/mju001.•• This is a recent review that focuses on new advances in understanding key functions of Wnts in mDA neuron development and in using novel tools to regulate Wnt signaling in regenerative medicine for Parkinson’s disease
127. Parish CL, Thompson LH. Modulating Wnt signaling to improve cell replacement therapy for Parkinson’s disease. J Mol Cell Biol. 2014;6:54–63. DOI:10.1093/jmcb/mjt045
128. Altarche-Xifro W, Di Vicino U, Munoz-Martin MI, et al. Functional rescue of dopaminergic neuron loss in parkinson’s disease mice after transplantation of hematopoietic stem and progenitor cells. EBioMedicine. 2016;8:83–95. DOI:10.1016/j.ebiom.2016.04.016
129. Sakata T, Chen JK. Chemical ‘Jekyll and Hyde’s:small-molecule inhibitors of developmental signaling pathways. Chem Soc Rev. 2011;40:4318–4331. DOI:10.1039/c1cs15019g
130. Chandrasekaran G, Tatrai P, Gergely F. Hitting the brakes:targeting microtubule motors in cancer. Br J Cancer. 2015;113:693–698. DOI:10.1038/bjc.2015.264
131. Higa GM, Sypult C. Molecular biology and clinical mitigation of cancer treatment-induced neuropathy. Clin Med Insights Oncol. 2016;10:27–34. DOI:10.4137/CMO.S32810
132. Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell. 1982;31:99–109.
133. Takebe N, Miele L, Harris PJ, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells:clinical update. Nat Rev Clin Oncol. 2015;12:445–464. DOI:10.1038/nrclinonc.2015.61